Members

LSCLogo.gif


Task Force Members
August 2009


Oren Cohen, Quintiles Transnational
Gregory Curt, AstraZeneca
James Doroshow, National Cancer Institute
Ana Maria Garcia, sanofi-aventis
Richard Gaynor, Eli Lilly
William Hait, Johnson & Johnson
Axel Hanuske, Eli Lilly
Judd Hartman, PPD
John Hohneker, Novartis
Gabe Leung, OSI Pharmaceuticals
Viren Mehta, Mehta Partners
Alan Metz, GlaxoSmithKline
Martin Murphy, CEO Roundtable on Cancer
Paolo Paoletti, GlaxoSmithKline
Phillip Porter, Hogan & Hartson
Sheila Prindiville, National Cancer Institute
Wayne Rackoff, Johnson & Johnson
Mace Rothenberg, Pfizer
Debasish Roychowdhury, sanofi-aventis
Jos Van Der Woert, Schering Plough

October 10 2008
CEO Roundtable on Cancer Offers “Common Language” to Jump Start Cancer Clinical Trials
- Partnership with National Cancer Institute, academic centers and industry could speed new therapies to cancer patients -
Read More

Standard Terms of Agreement for Research Trial (START) Clauses

StartCover.png Access to standardized legal language for Key elements can increase the efficiency of contract negotiations, resulting in reduced costs and accelerating the entry of new therapies into clinical trials.

Print Page Email Page to Friend Feedback
© 2010 by Life Sciences Consortium  All rights reserved.